Ines Tedeschi

Ines Tedeschi

Auto-generated profile, based on publicly available information

Ines Tedeschi

Cardiology Division, European Institute of Oncology, I.R.C.C.S., Milan, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2015 in Circulation
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
ACAlessandro Colombo
Alessandro Colombo
GBGiulia Bacchiani
Giulia Bacchiani
ITInes Tedeschi
Ines Tedeschi
CMCarlo A. Meroni
Carlo A. Meroni
CCCarlo M. Cipolla
Carlo M. Cipolla
Background—: Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting this classification are lacking. We prospectively evaluated incidence, time of occurrence, clinical correlates, and response to heart failure therapy of cardiotoxicity. Methods and Results—: We assessed left ventricular ejection fraction (LVEF), at baseline, every 3 months during chemotherapy and for the following year, every 6 months over the following 4 years, and yearly afterward in a heterogeneous cohort of 2625 patients receiving anthracycline-containing therapy. In case of cardiotoxicity (LVEF decrease >10 absolute points, and 5 absolute points and >50%) or full (LVEF increase to the baseline value). The median follow-up was 5.2 (quartile 1 to quartile 3, 2.6–8.0) years. The overall incidence of cardiotoxicity was 9% (n=226). The median time elapsed between the end of chemotherapy and cardiotoxicity development was 3.5 (quartile 1 to quartile 3, 3–6) months. In 98% of cases (n=221), cardiotoxicity occurred within the first year. Twenty-five (11%) patients had full recovery, and 160 (71%) patients had partial recovery. At multivariable analysis, end-chemotherapy LVEF (hazard ratio, 1.37; 95% confidence interval, 1.33–1.42 for each percent unit decrement) and cumulative doxorubicin dose (hazard ratio, 1.09; 95% confidence interval, 1.04–1.15 for each 50 mg/m 2 increment) were independent correlates of cardiotoxicity. Conclusions—: Most cardiotoxicity after anthracycline-containing therapy occurs within the first year and is associated with anthracycline dose and LVEF at the end of treatment. Early detection and prompt therapy of cardiotoxicity appear crucial for substantial recovery of cardiac function.

3 November 2010 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
alessandro testorialessandro testori
alessandro testori
GTGiulio Tosti
Giulio Tosti
CMChiara Martinoli
Chiara Martinoli
GSgiuseppe spadola
giuseppe spadola
FCFrancesco Cataldo
Francesco Cataldo
FFFerrucci Francesco
Ferrucci Francesco
Electroporation uses pulsed, high-intensity electric fields to temporarily increase cell membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal. The combination of electroporation with the administration of otherwise low-permeant cytotoxic drugs is known as electrochemotherapy (ECT). The two most commonly used drugs are bleomycin and cisplatin. ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile. ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.

1 August 2016 in Annals of Surgery
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
MSMaria T. Sandri
Maria T. Sandri
ACAlessandro Colombo
Alessandro Colombo
MSMichela Salvatici
Michela Salvatici
ITInes Tedeschi
Ines Tedeschi
CCCarlo M. Cipolla
Carlo M. Cipolla
We performed a prospective, randomized clinical study to assess whether prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in patients with elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces the incidence of postoperative atrial fibrillation. Postoperative atrial fibrillation is a well recognized complication after lung cancer surgery, with an incidence as high as 30%. Perioperative increase of NT-proBNP has been demonstrated to be a strong independent predictor of postoperative atrial fibrillation in this setting. NT-proBNP concentration was measured 24 hours before surgery and soon after surgery in 1116 patients. Three hundred twenty (29%) patients showed a high NT-proBNP value and were enrolled: 108 were assigned to the metoprolol group, 102 to the losartan group, and 110 to the control group. Overall, the incidence of postoperative atrial fibrillation was 20% (n = 64); it was significantly lower in the metoprolol and losartan groups compared with the control group [6%, 12%, and 40%, respectively; relative risk 0.19, 95% confidence intervals (CIs), 0.09-0.37; P < 0.001 in the metoprolol group; and 0.29, 95% CI, 0.16-0.52; P < 0.001 in the losartan group). No significant difference was found when the metoprolol and losartan groups were directly compared (P = 0.21). A prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in patients with high NT-proBNP levels, significantly reduced the occurrence of postoperative atrial fibrillation.

3 October 2005 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
GLGianluca Lazzaro
Gianluca Lazzaro
RLRoberta Lazzari
Roberta Lazzari
GPGiuseppe Pelosi
Giuseppe Pelosi
TPTommaso De Pas
Tommaso De Pas
LMLuigi Mariani
Luigi Mariani
alessandro testorialessandro testori
alessandro testori

26 January 2016 in Circulation
Verified
Journal Article
Closed access
DCDaniela Cardinale
Daniela Cardinale
ACAlessandro Colombo
Alessandro Colombo
GBGiulia Bacchiani
Giulia Bacchiani
ITInes Tedeschi
Ines Tedeschi
CMCarlo A. Meroni
Carlo A. Meroni
GCGiuseppe Curigliano
Giuseppe Curigliano